US Sales Expansion Turbett Surgical is actively expanding its US sales leadership, with the appointment of Sean Bogle as VP of US Sales and Bill Gerety as Chief Commercial Officer. This signals a growth-focused push ideal for business development outreach to hospitals and surgery centers. Target high-utilization ORs and ASCs with a compelling pilot offering to prove Instrument Pod can increase throughput and add an extra daily surgery.

OR Throughput ROI The Instrument Pod claims a 12% increase in room capacity when dedicating an OR to the device, translating into an additional surgery per day. Build a simple ROI toolkit showing incremental revenue, cost savings from reduced turnover, and payback periods to win procurement conversations.

Quality as Differentiator ISO 13485 certification positions Turbett as a quality-first supplier for sterile processing solutions. Leverage this to address procurement concerns around compliance, audits, and risk management; offer documentation, certifications, and post-deployment support as part of the value proposition.

Niche Growth Potential With a small-to-mid-sized footprint (11-50 employees) and revenue in the low-to-mid single digits, Turbett can compete effectively through rapid pilots, reference cases, and flexible terms. Consider partnerships with regional distributors or hospital networks to accelerate adoption and build a library of case studies.

Competitive Positioning The market includes mega-vendors like Cook Medical, Stryker, and Medtronic; Turbett’s focus on instrument processing and throughput optimization provides a differentiated, targeted value play for mid-market hospitals and ASCs seeking capacity gains and efficiency improvements. Position against larger players with tailored ROI stories and quick-start deployments.